Live Attenuated Vaccines (LAV) Market Growing Systematically at a Healthy CAGR of 10.7% During Forecast 2017-2023


Market Overview:
Acknowledging the exponential accruals the market witnesses today, Market Research Future (MRFR) in its recently published study report asserts that the global Live Attenuated Vaccines Market will reach USD 45.2 BN by 2023 with a CAGR of approximately 10.7% during the forecast period (2017-2023).
The Live Attenuated Vaccines (LAV) Market Size is growing at a rapid pace; mainly due to the increasing prevalence of bacterial and viral diseases. Moreover, rapidly spreading awareness towards the healthcare and the availability of various effective vaccines are escalating the market on the furthering heights. In 2016 The LAV market had evaluated at USD 34.2 BN.
Initiatives taken by the governments for vaccination against diseases such as influenza and others, alongside the excellent management of public awareness programs are some of the major driving force behind the accelerating Live Attenuated Vaccines Market. Furthermore, increasing awareness about vaccination, and growing government funding for vaccination programs along with the increasing prevalence of infectious diseases act as a tailwind propelling the market growth of LAV.
The Live Attenuated Vaccines Market Share is one of the fastest growing markets. Huge funding is being transpired in the research & development of LA vaccines. The growth of the market is expected to be driven by rising R&D funding, increasing awareness due to the prevention programs, and the growing number of new entrants in the market. Also, the improving healthcare infrastructure, increasing demand for LAV, and the emphasis on prevention of diseases foster the market growth.
Key Players:
·         Merck & Co
·         GlaxoSmithKline
·         Pfizer
·         Johnson & Johnson
·         Astellas Pharma Inc
·         CSL Limited
·         MedImmune
·         Sanofi
·         Emergent BioSolutions
Live Attenuated Vaccines Market  - Segmentation
MRFR has segmented its analysis into four key dynamics for the convenience of understanding;

By Types       : Bacterial (BCG vaccine) and Viral Vaccines (oral polio vaccine (OPV), measles, rotavirus, and yellow fewer and others).
By Vaccine Developments: Tissue Culture, Embryonated Eggs, and Live Animals among others.
By End-Users                       : Hospitals, Clinics, Diagnostic Centers, and Research Institute among others.
By Regions                            :  Europe, North America, APAC and Rest-of-the-World.

Live Attenuated Vaccines Market   - Regional Analysis
The North American region accounts for the dominating market for live attenuated vaccines. Countries like Canada and the U.S. play important role in the growth of this market. Major factors such as the augmenting demand for effective vaccines to control the growing prevalence of viral infections. High per capita health care expenditures along with the rising funds invested into R&D for the development of new vaccines are supporting the growth of the market in the region. Furthermore, Initiatives taken by the government for vaccination against diseases like influenza, as well as excellent management of public awareness programs are acting as a tailwind propelling the growth of the market for LAV.
The European region is the second-largest market for live attenuated vaccines which is estimated to witness extensive growth throughout the forecast period.  Growing emphasis and growing emphasis on R&D and the government financial support for research and development activities drive the market growth of LAV in the region. 
The live attenuated vaccines market in the Asia Pacific region is emerging as one of the lucrative markets, globally. Growing prevalence of bacterial and viral diseases alongside the increase in the prevalence of communicable diseases are few of the key driving forces pushing up the growth of the LAV market in the region. Owing to the large advancements in medical technology, India is emerging as the fastest growing market for LAV.

Live Attenuated Vaccines Market   - Competitive Analysis
The successful development of live attenuated vaccines almost positively depends on the involvement of both, private and public sectors from around the world. Currently, most of the government companies have the resources and encouragement to take on the challenge of developing live attenuated vaccines alone. Within the public sector, the development of live attenuated vaccines is important for a number of different agencies, which includes health concerns and the economic growth.
Substantial investments are being transpired by the key players into R&D to develop safe, effective, and affordable vaccines that can prevent various infections in uninfected people with the research priority giving its game-changing potential for controlling and ultimately ending the pandemics.


Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more